UTMD utahmed.com: Company Value to Revenue

Official company branding of Utah Medical Products, Inc. (UTMD)

Stable cash flow from neonatologist consumables guarantees business resilience. This EV/Sales multiplier chart from GURU.Markets confirms this trend, with the parameter stabilizing at 3355.67. The trust of medical specialists supports the brand's authority, while strict quality control and a conservative approach to hiring engineers ensure the internal financial reliability of Utah Medical Products (UTMD).

utahmed.com (UTMD): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

UTMD (Utah Med): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
Manufactured products of Utah Medical

Investors are assessing the long-term sustainability of Utah Medical Products (UTMD) through the lens of the business's enterprise value to annual revenue. This indicator aggregates market capitalization and net debt, dividing them by revenue to determine the actual price per unit of sales. Analyzing the ratio of company value to revenue allows for the identification of overvalued assets. The stability of this metric is critical in the presence of litigation and regulatory barriers. A decline in this metric may signal falling margins due to the technological obsolescence of products.

Direct competitors

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|TKNO - EV/Sales Multiple|Monogram Technologies Inc (MGRM) - Enterprise Value-to-Revenue Ratio|STSS - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio InfuSystem Holdings, Inc.|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple